Marketplace®
Every story is an economic story

New gene therapy drug expected to hit market with head-spinning price tag

Industry analysts expect the price for the single-treatment therapy to be anywhere from $1.5 million to $5 million.

Swiss pharmaceutical giant Novartis' Basel headquarters.
Swiss pharmaceutical giant Novartis' Basel headquarters.
SEBASTIEN BOZON/AFP/Getty Images

The Food and Drug Administration is expected to approve a new gene therapy drug from pharmaceutical company Novartis by the end of May.  

  • Zolgensma is a treatment for spinal muscular atrophy

  • Hundreds of children are born in the United States each year with the genetic, muscle-wasting disorder that kills many sufferers before they reach their second year

  • Industry analysts expect the price for the single-treatment therapy to be from $1.5 million to $5 million

  • Insurance companies might be reluctant to cover the drug

  • Zolgensma represents a coming wave of gene therapy drugs that likely will carry whopping price tags


Related Topics

Latest Episodes

View All Shows
  • Marketplace
    6 hours ago
    25:45
  • Marketplace Morning Report
    13 hours ago
    7:02
  • Marketplace Tech
    18 hours ago
    7:01
  • This Is Uncomfortable
    5 days ago
    42:59
  • Million Bazillion
    14 days ago
    29:48
  • Make Me Smart
    5 months ago
    24:33